EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel formylpeptide receptor 1/2 agonist limits hypertension-induced cardiovascular damage

Jaideep Singh iD, Kristy L Jackson iD, Haoyun Fang iD, Audrey Gumanti, Bethany Claridge, Feng Shii Tang iD, Helen Kiriazis iD, Ekaterina Salimova iD, Alex M Parker, Cameron Nowell iD, Owen L Woodman iD, David W Greening iD und 3 weitere

Cardiovascular Research · 2024

DOI: 10.1093/cvr/cvae103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, 2024. Verfasst von Jaideep Singh und 14 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia. Hauptthemen laut MEDLINE: Angiotensin II, Disease Models, Animal, Fibrosis, Hypertension. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vanguard, NHMRC Future Fund, NHMRC Ideas Grants.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Formylpeptide receptors (FPRs) play a critical role in the regulation of inflammation, an important driver of hypertension-induced end-organ damage. We have previously reported that the biased FPR small-molecule agonist, compound17b (Cmpd17b), is cardioprotective against acute, severe inflammatory insults. Here, we reveal the first compelling evidence of the therapeutic potential of this novel FPR agonist against a longer-term, sustained inflammatory insult, i.e. hypertension-induced end-organ damage. The parallels between the murine and human hypertensive proteome were also investigated. Methods and results The hypertensive response to angiotensin II (Ang II, 0.7 mg/kg/day, s.c.) was attenuated by Cmpd17b (50 mg/kg/day, i.p.). Impairments in cardiac and vascular function assessed via echocardiography were improved by Cmpd17b in hypertensive mice. This functional improvement was accompanied by reduced cardiac and aortic fibrosis and vascular calcification. Cmpd17b also attenuated Ang II-induced increased cardiac mitochondrial complex 2 respiration. Proteomic profiling of cardiac and aortic tissues and cells, using label-free nano-liquid chromatography with high-sensitivity mass spectrometry, detected and quantified ∼6000 proteins. We report hypertension-impacted protein clusters associated with dysregulation of inflammatory, mitochondrial, and calcium responses, as well as modified networks associated with cardiovascular remodelling, contractility, and structural/cytoskeletal organization. Cmpd17b attenuated hypertension-induced dysregulation of multiple proteins in mice, and of these, ∼110 proteins were identified as similarly dysregulated in humans suffering from adverse aortic remodelling and cardiac hypertrophy.

Conclusion

We have demonstrated, for the first time, that the FPR agonist Cmpd17b powerfully limits hypertension-induced end-organ damage, consistent with proteome networks, supporting development of pro-resolution FPR-based therapeutics for treatment of systemic hypertension complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin IIDisease Models, AnimalFibrosisHypertensionProteomicsReceptors, Formyl PeptideAnimalsHumansMaleMiceAnti-Inflammatory AgentsAntihypertensive AgentsAortaBlood PressureMice, Inbred C57BLMitochondria, HeartMyocytes, CardiacSignal TransductionVascular RemodelingVentricular Remodeling

Stichwörter der Autor:innen

Angiotensin IICompound17bEnd-organ damageFormylpeptide receptorsHypertensionProteomics

Substanzen

Angiotensin IIAnti-Inflammatory AgentsAntihypertensive AgentsFPR1 protein, humanReceptors, Formyl Peptide

Autor:innen und Institutionen

  • Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia.
  • Baker Heart & Diabetes Institute, 75 Commercial Rd, Melbourne, VIC 3004, Australia.
  • Department of Cardiometabolic Health, University of Melbourne, Melbourne, VIC, Australia.
  • Monash Biomedical Imaging, Monash University, Clayton, Melbourne, VIC, Australia.
  • Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Department of Cardiovascular Research, Translation and Implementation, La Trobe University, Melbourne, VIC, Australia.

ORCID-Profile: Jaideep Singh, Kristy L Jackson, Haoyun Fang, Feng Shii Tang, Helen Kiriazis, Ekaterina Salimova, Cameron Nowell, Owen L Woodman, David W Greening, Rebecca H Ritchie, Geoffrey A Head, Cheng Xue Qin

Förderung

  • Vanguard
  • NHMRC Future Fund
  • NHMRC Ideas Grants

Zitieren

APA

Singh, J., Jackson, K. L., Fang, H., Gumanti, A., Claridge, B., Tang, F. S., Kiriazis, H., Salimova, E., Parker, A. M., Nowell, C., Woodman, O. L., Greening, D. W., Ritchie, R. H., Head, G. A., & Qin, C. X. (2024). Novel formylpeptide receptor 1/2 agonist limits hypertension-induced cardiovascular damage. Cardiovascular Research. https://doi.org/10.1093/cvr/cvae103

Vancouver

Singh J, Jackson KL, Fang H, Gumanti A, Claridge B, Tang FS, et al. Novel formylpeptide receptor 1/2 agonist limits hypertension-induced cardiovascular damage. Cardiovascular Research. 2024. doi:10.1093/cvr/cvae103

BibTeX
@article{Singh2024,
  author = {Singh, Jaideep and Jackson, Kristy L and Fang, Haoyun and Gumanti, Audrey and Claridge, Bethany and Tang, Feng Shii and Kiriazis, Helen and Salimova, Ekaterina and Parker, Alex M and Nowell, Cameron and Woodman, Owen L and Greening, David W and Ritchie, Rebecca H and Head, Geoffrey A and Qin, Cheng Xue},
  title = {Novel formylpeptide receptor 1/2 agonist limits hypertension-induced cardiovascular damage},
  journal = {Cardiovascular Research},
  year = {2024},
  doi = {10.1093/cvr/cvae103}
}
Kostenlos starten →